Market Update: Oil Prices Slide Amid Tech Stock Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Should l Buy MRK?
Source: CNBC
- Oil Price Impact: Oil prices have dropped below $90 per barrel due to hopes for a truce between the U.S. and Iran, which could positively influence the stock market, as falling oil prices generally lead to a more favorable outlook for equities despite Iran's denial of ceasefire intentions.
- Surge in Arm Chip Demand: Arm's first in-house designed AGI CPU chip has seen incredible demand, with projections of $15 billion in revenue by 2031, prompting Raymond James to upgrade its stock rating from hold to buy, resulting in a 12% increase in share price, aligning with Nvidia's GPU performance.
- OpenAI Fundraising Milestone: OpenAI has raised an additional $10 billion from investors, bringing its total fundraising in this round to over $120 billion, with significant participation from institutions like Microsoft, indicating strong market confidence in its future growth potential.
- Merck's Strategic Acquisition: Merck is acquiring cancer biotech Terns Pharmaceuticals for $6.7 billion to bolster its oncology portfolio ahead of the 2028 patent expiration of its top-selling drug Keytruda, highlighting Merck's strategic focus on cancer treatment advancements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 117.100
Low
95.00
Averages
119.53
High
139.00
Current: 117.100
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Grants Approval for Merck's Once-Daily IDVYNSO™ (Doravirine/Islatravir)
FDA Approval: The FDA has approved Merck's once-daily oral antiviral medication, known as Islatravir, for the treatment of HIV.
Medication Details: The drug is marketed under the name DORAVIRINE and is designed to simplify HIV treatment regimens for patients.
See More
Merck & Co Inc: FDA Establishes PDUFA Action Date for August 17, 2026
- Merck & Co. Announcement: Merck & Co. has set a target action date of August 17, 2026, for its product under review by the FDA.
- FDA Review Process: The announcement indicates that the FDA is currently evaluating Merck's submission, with a decision expected by the specified date.
See More
FDA Approves Priority Review for Keytruda® and Keytruda Qlex™ in Combination with Padcev® for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin
FDA Grants Priority Review: The FDA has granted priority review for two drugs, Keytruda® (pembrolizumab) and Keytruda QLEX™ (pembrolizumab and berahyaluronidase), aimed at treating muscle-invasive bladder cancer.
Indication for Eligible Patients: These treatments are specifically for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.
See More
Merck's Kidney Cancer Drug Trial Fails to Meet Goals
- Trial Results Disappoint: Merck's kidney cancer treatment, developed in partnership with Eisai, failed to meet primary goals in the Phase 3 LITESPARK-012 trial, resulting in a 3.8% drop in stock price during the afternoon session, marking a significant setback for Merck's oncology pipeline.
- Market Reaction Intensifies: Although Merck's shares have shown low volatility over the past year, today's decline indicates that the market considers this news significant, raising investor concerns about the company's future profit outlook, especially with the impending patent expiration of its blockbuster drug, Keytruda.
- Historical Performance Review: Merck's stock has risen 5.8% since the beginning of the year, currently trading at $112.67 per share, close to its 52-week high of $123.93, reflecting relative stability in the market, but this trial failure may impact future investor confidence.
- Investment Opportunity Analysis: Despite the current stock price drop, there remains an opportunity for investors to consider buying high-quality stocks like Merck, as analysts suggest that this could be a strategic time to increase holdings in anticipation of potential market fluctuations.
See More
US Stocks Rise on Strong Retail Sales and Earnings Reports
- Strong Retail Sales: US March retail sales rose 1.7% month-over-month, exceeding expectations of 1.4% and marking the largest increase in a year, indicating robust consumer spending that could bolster economic recovery and market confidence.
- Earnings Support: UnitedHealth Group (UNH) reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, raising its full-year forecast to above $18.25, which has driven health insurance stocks higher and reflects industry resilience.
- Fed Nomination in Focus: Kevin Warsh's confirmation hearing before the Senate Banking Committee is drawing attention; despite facing an investigation hurdle, Warsh's commitment to an independent Fed and prioritizing inflation control could influence future monetary policy directions.
- International Tensions Impact Oil Prices: WTI crude oil prices fell over 1% as Iran is set to attend peace talks with the US, while the closure of the Strait of Hormuz threatens to exacerbate the global energy crisis, affecting market sentiment.
See More
U.S. Stocks Mixed as Oil Prices Rebound
- Market Performance: The S&P 500 Index fell by 0.13%, and the Dow Jones Industrial Average also declined by 0.13%, while the Nasdaq 100 saw a slight increase of 0.02%, reflecting market volatility influenced by oil price rebounds and economic data.
- Strong Economic Data: March retail sales rose by 1.7% month-over-month, exceeding expectations of 1.4%, marking the largest increase in a year, indicating robust consumer spending that may support stock prices.
- Oil Price Recovery: WTI crude oil prices rebounded by over 2% as market speculation intensified regarding Iran's participation in upcoming peace talks, potentially exacerbating the global energy crisis.
- Impressive Earnings Reports: UnitedHealth Group reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, leading to a stock price increase of over 7% and raising its full-year earnings forecast, showcasing strong performance in the health insurance sector.
See More
FDA Grants Approval for Merck's Once-Daily IDVYNSO™ (Doravirine/Islatravir)
FDA Approval: The FDA has approved Merck's once-daily oral antiviral medication, known as Islatravir, for the treatment of HIV.
Medication Details: The drug is marketed under the name DORAVIRINE and is designed to simplify HIV treatment regimens for patients.
See More
Merck & Co Inc: FDA Establishes PDUFA Action Date for August 17, 2026
- Merck & Co. Announcement: Merck & Co. has set a target action date of August 17, 2026, for its product under review by the FDA.
- FDA Review Process: The announcement indicates that the FDA is currently evaluating Merck's submission, with a decision expected by the specified date.
See More
FDA Approves Priority Review for Keytruda® and Keytruda Qlex™ in Combination with Padcev® for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin
FDA Grants Priority Review: The FDA has granted priority review for two drugs, Keytruda® (pembrolizumab) and Keytruda QLEX™ (pembrolizumab and berahyaluronidase), aimed at treating muscle-invasive bladder cancer.
Indication for Eligible Patients: These treatments are specifically for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.
See More
Merck's Kidney Cancer Drug Trial Fails to Meet Goals
- Trial Results Disappoint: Merck's kidney cancer treatment, developed in partnership with Eisai, failed to meet primary goals in the Phase 3 LITESPARK-012 trial, resulting in a 3.8% drop in stock price during the afternoon session, marking a significant setback for Merck's oncology pipeline.
- Market Reaction Intensifies: Although Merck's shares have shown low volatility over the past year, today's decline indicates that the market considers this news significant, raising investor concerns about the company's future profit outlook, especially with the impending patent expiration of its blockbuster drug, Keytruda.
- Historical Performance Review: Merck's stock has risen 5.8% since the beginning of the year, currently trading at $112.67 per share, close to its 52-week high of $123.93, reflecting relative stability in the market, but this trial failure may impact future investor confidence.
- Investment Opportunity Analysis: Despite the current stock price drop, there remains an opportunity for investors to consider buying high-quality stocks like Merck, as analysts suggest that this could be a strategic time to increase holdings in anticipation of potential market fluctuations.
See More
US Stocks Rise on Strong Retail Sales and Earnings Reports
- Strong Retail Sales: US March retail sales rose 1.7% month-over-month, exceeding expectations of 1.4% and marking the largest increase in a year, indicating robust consumer spending that could bolster economic recovery and market confidence.
- Earnings Support: UnitedHealth Group (UNH) reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, raising its full-year forecast to above $18.25, which has driven health insurance stocks higher and reflects industry resilience.
- Fed Nomination in Focus: Kevin Warsh's confirmation hearing before the Senate Banking Committee is drawing attention; despite facing an investigation hurdle, Warsh's commitment to an independent Fed and prioritizing inflation control could influence future monetary policy directions.
- International Tensions Impact Oil Prices: WTI crude oil prices fell over 1% as Iran is set to attend peace talks with the US, while the closure of the Strait of Hormuz threatens to exacerbate the global energy crisis, affecting market sentiment.
See More
U.S. Stocks Mixed as Oil Prices Rebound
- Market Performance: The S&P 500 Index fell by 0.13%, and the Dow Jones Industrial Average also declined by 0.13%, while the Nasdaq 100 saw a slight increase of 0.02%, reflecting market volatility influenced by oil price rebounds and economic data.
- Strong Economic Data: March retail sales rose by 1.7% month-over-month, exceeding expectations of 1.4%, marking the largest increase in a year, indicating robust consumer spending that may support stock prices.
- Oil Price Recovery: WTI crude oil prices rebounded by over 2% as market speculation intensified regarding Iran's participation in upcoming peace talks, potentially exacerbating the global energy crisis.
- Impressive Earnings Reports: UnitedHealth Group reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, leading to a stock price increase of over 7% and raising its full-year earnings forecast, showcasing strong performance in the health insurance sector.
See More
